Stockreport

Immunovant Announces Positive Clinical Results from Ongoing Phase 2a Proof-of-Concept Study of IMVT-1401, A Novel Investigational Anti-FcRn Antibody Delivered by Subcutaneous Injection, in...

Immunovant, Inc.  (IMVT) 
PDF Company to Host Conference Call on March 30, 2020 at 8:30am EDT 65% mean reduction in total IgG was observed from baseline to end of treatment, with a pharmacodynamic ( [Read more]